ATE535612T1 - Toxizitätsscreeningverfahren - Google Patents

Toxizitätsscreeningverfahren

Info

Publication number
ATE535612T1
ATE535612T1 AT07752400T AT07752400T ATE535612T1 AT E535612 T1 ATE535612 T1 AT E535612T1 AT 07752400 T AT07752400 T AT 07752400T AT 07752400 T AT07752400 T AT 07752400T AT E535612 T1 ATE535612 T1 AT E535612T1
Authority
AT
Austria
Prior art keywords
toxicity
concentration
determining
cell type
present
Prior art date
Application number
AT07752400T
Other languages
English (en)
Inventor
James Mckim
Original Assignee
Ceetox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceetox Inc filed Critical Ceetox Inc
Application granted granted Critical
Publication of ATE535612T1 publication Critical patent/ATE535612T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT07752400T 2006-03-06 2007-03-06 Toxizitätsscreeningverfahren ATE535612T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77966006P 2006-03-06 2006-03-06
US74359906P 2006-03-21 2006-03-21
PCT/US2007/005696 WO2007103374A2 (en) 2006-03-06 2007-03-06 Toxicity screening methods

Publications (1)

Publication Number Publication Date
ATE535612T1 true ATE535612T1 (de) 2011-12-15

Family

ID=38475502

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07752400T ATE535612T1 (de) 2006-03-06 2007-03-06 Toxizitätsscreeningverfahren

Country Status (4)

Country Link
US (3) US7615361B2 (de)
EP (2) EP1996718B1 (de)
AT (1) ATE535612T1 (de)
WO (1) WO2007103374A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101484806A (zh) 2006-05-17 2009-07-15 协乐民公司 一种对组织进行自动分析的方法
TW200927060A (en) 2007-11-05 2009-07-01 Kci Licensing Inc Identification of tissue for debridement
BRPI0912175A2 (pt) * 2008-05-28 2015-10-06 Basf Se métodos para diagnosticar indução de enzima do fígado, para determinar se um composto é capaz de induzir indução de enzima do fígado em um indivíduo, e para identificar uma substância para tratar indução de enzima do fígado
EP2294412A1 (de) * 2008-06-04 2011-03-16 Ceetox Inc. Verfahren zur vorhersage der hautsensibilisierungswirkung von verbindungen
WO2010094694A1 (en) * 2009-02-23 2010-08-26 F. Hoffmann-La Roche Ag Assays to predict cardiotoxicity
WO2010141954A1 (en) * 2009-06-06 2010-12-09 Ceetox, Inc. Method for predicting respiratory toxicity of compounds
US20110081675A1 (en) * 2009-10-06 2011-04-07 Wisconsin Alumni Research Foundation Metabolic Biomarkers Of Drug-Induced Cardiotoxicity
US20110212461A1 (en) * 2010-02-26 2011-09-01 Hans Marcus Ludwig Bitter Prediction of cardiotoxicity
US20110212480A1 (en) * 2010-02-26 2011-09-01 Kyle Louis Kolaja Use of primary human cardiomyocytes
US20120179381A1 (en) * 2010-06-17 2012-07-12 Mckim James M Toxicity screening methods
US8715646B2 (en) 2010-07-29 2014-05-06 The Board Of Trustees Of The University Of Illinois Methods of determining need for anti-coagulation therapy
ES2739623T3 (es) 2011-03-17 2020-02-03 Cernostics Inc Sistemas y composiciones para diagnosticar el esófago de Barrett y métodos para usarlos
EP2574924A1 (de) 2011-09-28 2013-04-03 Merck Patent GmbH Verfahren zur Bestimmung des Status von Zellen
US10852296B2 (en) * 2011-12-27 2020-12-01 BiOMICom Incorporated Micro-sampling for cell, tissue, and micro-organism monitoring
WO2013116307A1 (en) 2012-01-30 2013-08-08 Mount Sinai School Of Medicine Method for programming differentiated cells into hematopoietic stem cells
WO2013176694A1 (en) * 2012-05-22 2013-11-28 Berg Pharma Llc Interrogatory cell-based assays for indentifying drug-induced toxicity markers
US10352947B2 (en) 2012-09-12 2019-07-16 Berg Llc Use of markers in the identification of cardiotoxic agents and in the diagnosis and monitoring of cardiomyopathy and cardiovascular disease
US20180224430A1 (en) * 2015-08-18 2018-08-09 Coyne Scientific, Llc Method of Estimating the Incidence of In Vivo Reactions to Chemical or Biological Agents Using In Vitro Experiments
CN106770693A (zh) * 2015-11-19 2017-05-31 中国药科大学 新型药物体外温孵、代谢物寻找、药物-药物相互作用预测快速筛选与分析整合策略
GB201700138D0 (en) 2017-01-05 2017-02-22 Senzagen Ab Analytical methods and arrays for use in the same
KR20230044440A (ko) * 2020-07-24 2023-04-04 더 유니버시티 오브 털사 N-벤질 설폰아미드의 합성 및 사용
CN115616134A (zh) * 2022-10-24 2023-01-17 南京理工大学 一种新污染物转化效应的评估系统
CN117169091B (zh) * 2023-07-28 2024-09-13 恩大细胞基因工程有限公司 一种细胞活性检测系统
US20250316343A1 (en) * 2024-03-08 2025-10-09 AxiomBio, Inc. Optimizing molecule toxicity by replacing target fragments with bioisosteres

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL62879A (en) * 1981-05-15 1985-09-29 Chaya Moroz Monoclonal antibodies,clones producing them,preparation of such antibodies and clones and cytotoxic and immunoassay using such antibodies
US4532751B1 (en) 1984-04-16 1998-02-03 Mayer Oskar Foods Automatic sheet product line
GB9221664D0 (en) 1992-10-15 1992-11-25 Shiny Chemical Ind Co Limited Propylene glycol monomethyl ether propionate and the process for the preparation thereof
JPH10500112A (ja) 1994-05-06 1998-01-06 ファーマコピーア,インコーポレイテッド 組合せ ジヒドロベンゾピラン ライブラリー
JPH10500685A (ja) 1994-05-23 1998-01-20 アーキュール,インコーポレーテッド 少なくとも2つの構造多様性要素をもつアミンイミドおよびオキサゾロンをベースとした分子の系統的モジュール製造
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
WO1997049653A2 (en) 1996-06-24 1997-12-31 Irori Solid phase tyrphostin library linked to matrices with memories
US6558916B2 (en) * 1996-08-02 2003-05-06 Axiom Biotechnologies, Inc. Cell flow apparatus and method for real-time measurements of patient cellular responses
US5985268A (en) * 1997-09-15 1999-11-16 Lockheed Martin Energy Research Corp. Gamma-irradiated bacterial preparation having anti-tumor activity
US6998249B1 (en) * 1999-09-27 2006-02-14 Pharmacia & Upjohn Company Toxicity screening method

Also Published As

Publication number Publication date
US20110008823A1 (en) 2011-01-13
WO2007103374A3 (en) 2008-11-27
EP1996718A4 (de) 2009-11-25
EP1996718B1 (de) 2011-11-30
US20070218457A1 (en) 2007-09-20
WO2007103374A9 (en) 2009-01-15
EP2287327A1 (de) 2011-02-23
US20130252270A1 (en) 2013-09-26
EP1996718A2 (de) 2008-12-03
EP2287327B1 (de) 2013-06-05
US7615361B2 (en) 2009-11-10
WO2007103374A2 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
EP1996718A4 (de) Toxizitätsscreeningverfahren
GB2474146A (en) Methods of determining the health status of an individual
ATE428929T1 (de) Reagens, ausstattung und verfahren zur probenanalyse
ATE438853T1 (de) Diagnostische testvorrichtung
NO339224B1 (no) Bedrede immunprøvemetoder
ATE527543T1 (de) Testvorrichtung zur schnelldiagnose
EP2340300A4 (de) Verfahren zur erkennung von analyten
GB0612649D0 (en) No title
DK2021794T3 (da) Anvendelse af protein S100A 12 som en markør for colorektal cancer
EP2134724A4 (de) Reagentien zum nachweis von hypochloriger säure
ATE531820T1 (de) Gesundheitszustandstest
MX2009006159A (es) Elemento de prueba con referencia.
DK2038430T3 (da) Toll-Like-Receptor-4-dysfunktion og de biologiske anvendelser deraf
WO2011021041A3 (en) Survival prognostic assay
ATE541216T1 (de) Fluoreszenztestverfahren
MX2009010751A (es) Composiciones y metodos de deteccion.
KR100711046B1 (ko) 대장암에 대한 마커로서의 니코틴아미드n―메틸트랜스퍼라아제의 용도
CY1112423T1 (el) Αναλυτικη συσκευη μικροεπεξεργαστη μιας χρησης
ATE437370T1 (de) Pharmakodynamische tests mit durchflusszytometrie
DE602005014386D1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
FI20040255A7 (fi) Menetelmä pre-eklampsian riskin havaitsemiseksi
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
DE602007004570D1 (de) Verwendung von Nogo-C bei der Beurteilung von Herzversagen
DE602004001994D1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs